|
|
Volumn 91, Issue 1, 2003, Pages 115-116
|
|
As we enter the new year, several new drugs will be launched globally
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADRENERGIC RECEPTOR BLOCKING AGENT;
ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;
ANDROGEN;
APOMORPHINE;
DARIFENACIN;
DOPAMINE RECEPTOR STIMULATING AGENT;
DUTASTERIDE;
FIDUXOSIN;
FINASTERIDE;
MUSCARINIC RECEPTOR BLOCKING AGENT;
NEW DRUG;
OXYBUTYNIN;
PARVOSIN;
PHENTOLAMINE;
PHOSPHODIESTERASE INHIBITOR;
RBX 2258;
RXS 70004;
SILDENAFIL;
SOLIFENACIN;
STEROID 5ALPHA REDUCTASE;
STEROID 5ALPHA REDUCTASE INHIBITOR;
TADALAFIL;
TAMSULOSIN;
TOLTERODINE;
UK 380003;
UNCLASSIFIED DRUG;
VARDENAFIL;
CARDIOVASCULAR EFFECT;
DRUG EFFICACY;
ECONOMIC ASPECT;
ERECTILE DYSFUNCTION;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE;
HUMAN;
LONG TERM CARE;
PATIENT COMPLIANCE;
PRIORITY JOURNAL;
PROSTATE HYPERTROPHY;
SHORT SURVEY;
SIDE EFFECT;
TREATMENT OUTCOME;
URGE INCONTINENCE;
URINE RETENTION;
DRUG DESIGN;
DRUG INDUSTRY;
FORECASTING;
HUMANS;
UROLOGIC DISEASES;
|
|
EID: 0037236338
PISSN: 14644096
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1464-410X.2003.04007.x Document Type: Short Survey |
|
Times cited : (1)
|
|
References (0)
|
